Abbott has received CE Mark for its next-generation Xience Prime everolimus-eluting coronary stent system for the treatment of coronary artery disease. The company plans to launch Xience Prime in a varied size matrix, with lengths up to 38 mm, in the third quarter across Europe.
Xience Prime utilizes the same biocompatible polymer as Abbott's Xience V everolimus-eluting coronary stent system. However, the Abbott Park, Ill.-based company said the new drug-eluting stent (DES) offers a new stent design and a modified delivery system designed to improve flexibility and deliverability. Xience Prime uses cobalt chromium technology, allowing for thinner struts. Abbott also said its Xience Prime is based upon the design of the Multi-Link family of stents.
Upon its European launch, Xience Prime will be available in an expanded size matrix, including Xience Prime SV for small vessels and Xience Prime LL for long lesions.
As an investigational device in the U.S., Xience Prime is not available for sale.